Investors of Pacira BioSciences Targeted in Class Action Lawsuit Notification by Levi & Korsinsky

Overview of the Class Action Lawsuit Against Pacira BioSciences

Introduction
Levi & Korsinsky, LLP has alerted investors of Pacira BioSciences, Inc. regarding a class action securities lawsuit involving possible securities fraud. This lawsuit is particularly relevant for investors who faced losses due to the actions or omissions of the company during a specified period.

Details of the Allegations
The class action lawsuit focuses on events that happened between August 2, 2023, and August 8, 2024. During this period, Pacira allegedly engaged in misleading activities related to their flagship product and its patent status. On August 9, 2024, the company released a press statement detailing their unsuccessful lawsuit against eVenus for patent infringement. It was revealed that the court had deemed their U.S. Patent No. 11,033,495 invalid, indicating that eVenus was not infringing upon any intellectual property, which was a significant blow to Pacira. This patent is crucial as it is associated with Exparel, which generates approximately 80% of the company's revenue.

Analysts have expressed concerns that the invalidation of this patent could jeopardize Pacira's other patents, potentially leading to a rise in generic competitors and additional legal disputes. Following this negative announcement, the company’s stock witnessed a steep decline of over 47% in just one day—plummeting from a closing price of $22.36 to as low as $11.70 on August 9, 2024.

Who May Be Affected and Next Steps
Investors who suffered financial losses during this timeframe may be eligible for compensation by becoming part of this class action lawsuit. Interested individuals have until March 14, 2025, to request the court to appoint them as lead plaintiffs. However, one does not need to be a lead plaintiff to participate in any potential recovery from the lawsuit.

Crucially, if you qualify as a class member, participation in the lawsuit will incur no out-of-pocket costs. This approach ensures that individuals can seek remediation without facing additional financial burdens.

Why Choose Levi & Korsinsky?
For more than two decades, the team at Levi & Korsinsky has garnered hundreds of millions in recoveries for distressed shareholders, establishing a strong reputation in handling high-stakes litigation cases. The firm has extensive experience in representing investors in complex securities disputes, consisting of over 70 expert team members dedicated to client needs. The firm has consistently ranked among the top securities litigation firms in the United States, as recognized in ISS Securities Class Action Services' Top 50 Reports for seven consecutive years.

Contact Information
For further inquiries or to initiate claims, investors can reach out to Joseph E. Levi, Esq. at Levi & Korsinsky, LLP via email at [email protected] or by phone at (212) 363-7500. The firm is located at 33 Whitehall Street, 17th Floor, New York, NY 10004.

Conclusion

As the implications of this lawsuit unfold, affected investors are encouraged to assess their legal options for potential compensation through the ongoing class action that Levi & Korsinsky has initiated. The upcoming deadline provides an opportunity for those impacted by the company’s actions to be actively involved in seeking justice and restitution.